This is a working overview of G protein-coupled receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility class | Soluble in water and DMSO | Dissolves readily |
| Typical storage temperature | -20 °C or lower | Long-term, desiccated |
| Standard purity method | Reverse-phase HPLC | Area normalization |
| Freeze-thaw guidance | Limit to three cycles | Aliquot in advance |
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Follitropin subunit beta also known as follicle-stimulating hormone beta subunit (FSH-B) is a protein that in humans is encoded by the FSHB gene. Alternative splicing results in two transcript variants encoding the same protein.
It was during this early period when Jung was an assistant at the Anatomical Institute at Basel University, that he took an interest in paleoanthropology and the revolutionary discoveries of Homo erectus and Neanderthal fossils. These formative experiences contributed to his fascination with the evolutionary past of humanity and his belief that an ancient evolutionary layer in the psyche, represented by early fossil hominins, is still evident in the psychology of modern humans. Despite showing promise in medicine and almost choosing to specialise in surgery, Jung, to the dismay of his family and professors, decided to become a psychiatrist after reading a Richard von Krafft-Ebing's Textbook of Psychiatry. In December 1900, he moved to Zürich and began as an intern (voluntary doctor) at the Burghölzli psychiatric hospital under the psychiatrist Eugen Bleuler. Bleuler was already in communication with Sigmund Freud and introduced Jung to his work. At Burghölzli, Jung became interested in 'dementia praecox' (former name for schizophrenia, a term that Bleuler came up with). Before this he had mainly been interested in neurosis, but psychotic patients would become his primary concern for the rest of his career. In 1902, on leave from Burghölzli, Jung studied with Pierre Janet in Paris, and later equated his view of the complex with Janet's idée fixe subconsciente. In 1905, Jung was appointed as a permanent 'senior' doctor at Burghölzli and became a lecturer Privatdozent in the medical faculty of Zurich University.
1 of the 20 Greatest WWE Wrestlers Of All Time Texas Wrestling Alliance TWA Tag Team Championship (1 time) – with Rod Price World Championship Wrestling WCW World Television Championship (2 times) WCW United States Heavyweight Championship (2 times) WCW World Tag Team Championship (1 time) – with Brian Pillman NWA World Tag Team Championship (1 time) – with Brian Pillman World Wrestling Federation/World Wrestling Entertainment/WWE WWF Championship (6 times) WWF Intercontinental Championship (2 times) WWF Tag Team Championship (4 times) – with Shawn Michaels (1), Dude Love (1), The Undertaker (1), and Triple H (1) Million Dollar Championship (1 time) King of the Ring (1996) Royal Rumble (1997, 1998, 2001) Undisputed WWF Championship #1 Contenders Tournament (2002) Fifth Triple Crown Champion Slammy Award (2 times) Freedom of Speech (1997) Best Original WWE Network Show – Stone Cold Podcast (2015) WWE Hall of Fame (2 times) Class of 2009 – individually Class of 2025 – Immortal Moment vs. Bret Hart at WrestleMania 13 Wrestling Observer Newsletter Best Box Office Draw (1998, 1999) Best Brawler (2001) Best Gimmick (1997, 1998) Best Heel (1996) Best on Interviews (1996–1998, 2001) Best Non-Wrestler (2003) Feud of the Year (1997) vs. The Hart Foundation Feud of the Year (1998, 1999) vs. Vince McMahon Match of the Year (1997) vs. Bret Hart in a submission match at WrestleMania 13 Most Charismatic (1997, 1998) Rookie of the Year (1990) Tag Team of the Year (1993) with Brian Pillman as The Hollywood Blonds Worst Worked Match of the Year (1991) with Terrance Taylor vs.
=== Concrete exposed to hydrocarbon fires === Concrete cannot, by itself, withstand severe hydrocarbon fires. In the Channel Tunnel that connects the United Kingdom and France, an intense fire broke out and reduced the concrete lining in the undersea tunnel down to about 50 mm. In ordinary building fires, concrete typically achieves excellent fire-resistance ratings, unless it is too wet, which can cause it to crack and explode. For unprotected concrete, the sudden endothermic reaction of the hydrates and unbound humidity inside the concrete generates pressure high enough to spall off the concrete, which falls in small pieces on the floor of the tunnel. Humidity probes are inserted into all concrete slabs that undergo fire testing to test for this, even for the less severe building elements curve (DIN4102, ASTM E119, BS476, or ULC-S101). The need for fireproofing was demonstrated, among other fire protection measures, in the European "Eureka" Fire Tunnel Research Project, which gave rise to building codes for the trade to avoid the effects of such fires upon traffic tunnels. Cementitious spray fireproofing must be certification-listed and applied in the field as per that listing, using a hydrocarbon fire test curve such as the one used in UL1709.
Sources: en.wikipedia.org
wild type (WT) Denoted in shorthand with a + superscript. The phenotype of the typical form of a species as it occurs in nature; a product of the standard "normal" allele at a given locus, as opposed to that produced by a non-standard mutant allele.
=== Fatty acid uptake === Long chain fatty acid uptake is mediated by several transporters, including FAT (fatty acid translocase)/CD36. CD36 deletion rescues lipotoxic cardiomyopathy. FAT/CD36 may be controlled by insulin and AMPK. Increased transport coupled to the formation of the CoA derivatives and the resulting AMPK activation should ensure efficient fatty acid uptake and metabolism.
To what extent suicidal thoughts are influenced by behavioral symptoms is unclear, as they signify a desire to avoid the later stages of the disease. Suicide is the greatest risk of this disease before the diagnosis is made and in the middle stages of development throughout the disease. Other associated risks include choking due to the inability to swallow, physical injury from falls, and malnutrition.
== Terminology == Desmoplasia originates from the Ancient Greek δεσμός desmos, 'knot, bond' and πλάσις plasis, 'formation'. It is usually used in the description of desmoplastic small round cell tumors. Neoplasia is the medical term used for both benign and malignant tumors, or any abnormal, excessive, uncoordinated, and autonomous cellular or tissue growth.
Isabelle Adjani, actress Bilal Hassani, singer-songwriter and Eurovision Song Contest 2019 French representative Kevin Germanier, Swiss fashion designer Camille Cottin, actress Noam Sinseau, comedian and dancer Fatou Guinea, actress and entrepreneur Jessé Rémond Lacroix, comedian, writer and actor Ebony, singer Marguerite, singer-songwriter and actress Galia Salimo, dancer and vedette Vinii Revlon, ballroom dancer and choreographer Loreen, singer Thomas Jolly, actor and artistic director
Sources: en.wikipedia.org
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.
Repeated freeze-thaw cycles, alkaline pH, and exposure to light or oxygen are the main drivers. Moisture uptake by the solid also matters.
Mass spectrometry provides the strongest single identity check by matching the observed molecular ion to the expected value. Chromatographic retention time alone is not sufficient.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.